Skip to content
Screener

Ionis Pharmaceuticals IONS Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Eli Lilly logo
Eli LillyLLY
$7.34B+213%
Pfizer logo
PfizerPFE
$14.2B+6.8%
ALN
Alnylam PharmaceuticalsALNY
$9.15M-16.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$41M+136%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$991K-47.1%
CalAmp logo
CalAmpCAMP
$30K+1,400%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.06B+39.6%
Enterprise value$8.97B+28.4%
P/S10.4×+3.5×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemJune 30, 2026December 31, 2025
1.75 percent convertible senior notes due 2028, net569,255567,830
Liability related to sale of future royalties, net562,574551,353
Long-term lease liabilities262,476262,383
Long-term obligations28,43528,118
Total liabilities2,554,7643,034,747
Stockholders’ equity:
Common stock, $0.001 par value; 300,000,000 shares authorized, 165,636,792 and 163,304,875 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively166163
Additional paid-in capital3,311,8373,145,402

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's other non-current liabilities?
Ionis Pharmaceuticals (IONS) reported other non-current liabilities of $28.44M in Q2 2026.
How has Ionis Pharmaceuticals's other non-current liabilities changed year-over-year?
Ionis Pharmaceuticals's other non-current liabilities decreased by 51.9% year-over-year, from $59.07M to $28.44M.
What is the long-term trend for Ionis Pharmaceuticals's other non-current liabilities?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's other non-current liabilities has grown at a 41.8% compound annual growth rate (CAGR), from $6.95M to $28.12M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about Ionis Pharmaceuticals's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude